PharVision Advisers’s Transcat TRNS Stock Holding History

PharVision Advisers’s Portfolio TRNS Stock Details TRNS Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	–	Sell	-4,688	Closed	-$266K	–	603
2025 Q4	$266K	Buy	+4,688	New	+$292K	0.13%	350

Other funds holding TRNS

Neuberger Berman Group New York $150B AUM 40.08% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

HRCM

Hood River Capital Management Palm Beach Gardens, Florida $13.8B AUM 163.97% 1-Year Est. Return

Royce & Associates New York $12.4B AUM 64.17% 1-Year Est. Return

OAM

Ophir Asset Management Sydney, Australia $1.22B AUM 100.03% 1-Year Est. Return

CCA

Conestoga Capital Advisors Wayne, Pennsylvania $4.6B AUM 16.08% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Barrow, Hanley, Mewhinney & Strauss Dallas, Texas $33B AUM 40.62% 1-Year Est. Return

Riverbridge Partners Minneapolis, Minnesota $3.58B AUM 4.02% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return

PharVision Advisers's TRNS Position: Q1 2026 in Review

PharVision Advisers sold out of Transcat (TRNS) in Q1 2026, closing a stake of 4,688 shares — an estimated $266K sold.

PharVision Advisers first reported a position in TRNS in Q4 2025 and held it in 1 quarter. The position peaked at $266K in Q4 2025. 159 funds tracked by Wall St. Rank hold TRNS as of Q1 2026.

PharVision Advisers reported no remaining Transcat position as of Q1 2026 after selling out during the quarter.
PharVision Advisers sold 4,688 Transcat shares in Q1 2026, an estimated $266K.
PharVision Advisers first reported a position in Transcat in Q4 2025 and held it in 1 quarter.
PharVision Advisers's Transcat position peaked at $266K in Q4 2025.
159 funds tracked by Wall St. Rank held Transcat as of Q1 2026.

Based on PharVision Advisers's 13F filing for Q1 2026, filed 22 Apr 2026.